

## Interference between *Streptococcus pneumoniae* and *Staphylococcus aureus*: In Vitro Hydrogen Peroxide-Mediated Killing by *Streptococcus pneumoniae*

Gili Regev-Yochay,<sup>1\*</sup> Krzysztof Trzciński,<sup>1</sup> Claudette M. Thompson,<sup>1</sup>  
Richard Malley,<sup>2</sup> and Marc Lipsitch<sup>1</sup>

Department of Epidemiology and Department of Immunology & Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts,<sup>1</sup> and Division of Infectious Diseases, Department of Medicine, Children's Hospital and Harvard Medical School, Boston, Massachusetts<sup>2</sup>

Received 3 March 2006/Accepted 21 April 2006

**The bactericidal activity of *Streptococcus pneumoniae* toward *Staphylococcus aureus* is mediated by hydrogen peroxide. Catalase eliminated this activity. Pneumococci grown anaerobically or genetically lacking pyruvate oxidase (SpxB) were not bactericidal, nor were nonpneumococcal streptococci. These results provide a possible mechanistic explanation for the interspecies interference observed in epidemiologic studies.**

Nasal *Staphylococcus aureus* and nasopharyngeal *Streptococcus pneumoniae* colonization serve as a source for infection of other sites and for transmission between humans (12, 24). Epidemiological studies have suggested that nasopharyngeal carriage of *S. pneumoniae* may inhibit nasal carriage of *S. aureus* (4, 17). Hydrogen peroxide produced by *S. pneumoniae* has been reported to be toxic in vitro to other bacteria (11, 15) and to mammalian cells (2, 5, 9). H<sub>2</sub>O<sub>2</sub> is produced by pyruvate oxidase (SpxB) as a by-product of aerobic metabolism (19). We sought to test the hypothesis that *S. pneumoniae* directly inhibits *S. aureus* in vitro by an H<sub>2</sub>O<sub>2</sub>-dependent mechanism.

(The results of this study were partially presented at the 45th Interscience Conference of Antimicrobial Agents and Chemotherapy, Washington, D.C., October 2005.)

Bacterial strains used in this study are described in detail in Table 1. *S. pneumoniae* strains used were TIGR4 (21), Rx1 (16), and Pn-20. In addition, SpxB-negative variants of TIGR4 and Pn-20 and LytA-negative variants of Rx1 and Pn-20 were created using the Janus cassette (20). Strains of three other *Streptococcus* spp.—*S. gordonii*, group A streptococcus, and group C streptococcus—were also tested. Staphylococcal species used in the study were the following: *S. aureus* strains Newman (NCTC 8178) and ALR and coagulase-negative staphylococci (CNS) (*Staphylococcus epidermidis*, *Staphylococcus xylosum*, and *Staphylococcus sciuri*). Bovine liver catalase (1,000 U/ml; MP Biomedicals, Inc., Solon, OH) was added to growth medium when specified. Bacterial H<sub>2</sub>O<sub>2</sub> production was measured colorimetrically in culture supernatants (8).

To quantify bactericidal activity, we cocultured bacterial strains in brain heart infusion (BHI) and evaluated their survival on selective media. Serial twofold dilutions of the staphylococcal strain were mixed with twofold serial dilutions of the streptococcal strain in a final volume of 100  $\mu$ l (see legend to

Fig. 1 for more details). Cultures with and without catalase were incubated at 37°C in 5% CO<sub>2</sub>. At time zero and 6 h, approximately 2  $\mu$ l of each culture was plated on selective medium using a replica plater (Sigma, Aldrich).

For a given *S. aureus* inoculum, a higher *S. pneumoniae* inoculum led to greater killing (Fig. 1A and B). The diagonal pattern of killing (Fig. 1B) suggests that the inoculum of *S. aureus* that could be killed completely was approximately linearly proportional to the pneumococcal inoculum. Killing was eliminated by the addition of catalase (Fig. 1C to D). No inhibition of *S. pneumoniae* by *S. aureus* was observed (Fig. 1E to F).

To quantify bactericidal efficiency, we report the maximum staphylococcal inoculum “killed” (reduced below the detection limit of 50 CFU/well) by 10<sup>6</sup> CFU of streptococci at 6 h (IK6). Tables 2 and 3 compare the killing efficiencies of different streptococci and the susceptibilities of different staphylococci. SpxB-negative strains did not produce detectable amounts of H<sub>2</sub>O<sub>2</sub> and were minimally bactericidal to *S. aureus*. The maximum inoculum of *S. aureus* killed by *S. pneumoniae* Pn-20 $\Delta$ spxB was 1.2 log<sub>10</sub> CFU (IK6 = 1.2), 5 orders of magnitude lower than that of the parental strains (Table 2); catalase abolished the residual killing activity. Other streptococcal species that did not produce detectable levels of H<sub>2</sub>O<sub>2</sub> demonstrated little or no bactericidal effect (Table 2).

To verify that *S. aureus* is inhibited by a soluble factor produced by *S. pneumoniae* and that this factor is H<sub>2</sub>O<sub>2</sub>, we evaluated the growth of *S. aureus* (Newman) in filtered pneumococcal supernatant and compared it to growth in fresh BHI and in coculture with *S. pneumoniae* (Pn-20). Figure 2 demonstrates a bactericidal effect of sterile supernatant from aerobic cultures of *S. pneumoniae* to *S. aureus* within 6 h (Fig. 2A). This effect was mitigated either when catalase was added to the medium or with supernatant from anaerobically grown *S. pneumoniae*, which does not produce H<sub>2</sub>O<sub>2</sub> (14) (Fig. 2B).

*S. pneumoniae* variants lacking the major autolytic enzyme LytA exhibited bactericidal activities similar to those of their

\* Corresponding author. Mailing address: Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave., Boston, MA 02115. Phone: (617) 432-3269. E-mail: gregev@hsph.harvard.edu.

TABLE 1. Bacterial strains and primers used in this study

Strain or primer	Description	Source or reference
<i>S. pneumoniae</i>		
TIGR4	TIGR4 but streptomycin resistant by selection of mutants	21
TIGR4S	R6 derivative, <i>cbp3::kan-rpsL</i> <sup>+</sup>	22
CP1296	TIGR4S but <i>spbB::kan-rpsL</i> <sup>+</sup> by transformation with ligation product of PCR fragments amplified with primer pairs TTM211-TTM212 in TIGR4, DAM406-DAM351 in CP1296, and TTM213-TTM214 in TIGR4, and prior to ligation digested with BamHI, BamHI and Apal, respectively	20
TIGR4Δ <i>spbB</i>	Serotype 35B, nasopharyngeal human isolate	This study
Pn-20	Pn-20S but <i>spbB::kan-rpsL</i> <sup>+</sup> by transformation with TTM211-TTM214 PCR product of TIGR4Δ <i>spbB</i>	This study
Pn-20Δ <i>spbB</i>	Pn-20S but <i>hytA::kan-rpsL</i> <sup>+</sup> by transformation with LAD4-LAD1 PCR product of RxlΔ <i>hyt4</i>	This study
Pn-20Δ <i>hyt4</i>		18
Rx1		10
R6	Rx1 but streptomycin resistant by selection of mutants	This study
Rx1S	Rx1S but <i>hyt4::kan-rpsL</i> <sup>+</sup> by transformation with ligation product of PCR fragments amplified with primer pairs LAD4-LAD3 in R6, DAM406-DAM351 in CP1296, and LAD2-LAD1 in R6 and prior to ligation digested with BamHI, BamHI and Apal, and Apal, respectively	This study
RxlΔ <i>hyt4</i>		13
<i>S. gordonii</i> strain GP251		
Group A streptococcus strain 771		Kindly supplied by Michael Wessels
Group C streptococcus		This study
<i>S. aureus</i>		
Strain Newman	Nasal isolate from a Wistar rat	NCTC 8178
Strain ALR	Nasal isolate from an ICR mouse	Kindly supplied by Jean Lee
<i>S. seuri</i>		ATCC 35984
<i>S. epidermidis</i> strain RP62a		This study
<i>S. xylosox</i>	Nasal isolate from a C57BL/6 mouse	This study
Primers		
DAM406	TCTATGGCCTAATTCAGAGGAAATGGAT	22
DAM351	CTAGGGCCCCCTTCCCTTATGCTTTTGGAC	20
TTM211	CGTTAAGCGGAGGAGTGA corresponds to positions 1002-985 upstream of <i>spbB</i> in TIGR4	This study
TTM212	TTTGGATCCGATGCGAGTAATTTTCCCTTGAGTC positions 10-34 correspond to positions 26-3 within <i>spbB</i> in TIGR4	This study
TTM213	AAAGGGCCCTCTCGCCGAAATCAAATA positions 8-28 correspond to positions 3-23 downstream of <i>spbB</i> in TIGR4	This study
TTM214	CGCCACGTCGAGAACATCC corresponds to positions 1199-1181 downstream of <i>spbB</i> in TIGR4	This study
LAD1	CAAGGTATCCATCATTC corresponds to 1011-993 downstream of <i>hyt4</i> in R6	This study
LAD2	CGCGATCCACAGTAGAGCCAGATGGC positions 9-27 correspond to positions 921-939 within <i>hyt4</i> in R6	This study
LAD3	TTGGGCCCGTTGACAGCCGACTTGAGG positions 10-27 correspond to positions 37-54 within <i>hyt4</i> in R6	This study
LAD4	CTTTGCTTCTCAGAAATCTAGG corresponds to 850-830 upstream of <i>hyt4</i> in R6	This study




FIG. 1. Growth of *S. aureus* and *S. pneumoniae* on selective media after replica plating from cocultures. Columns of the plate contain twofold dilutions of the staphylococcal strain beginning with  $4 \times 10^7$  CFU/ml in the left column. Rows contain twofold dilutions of the streptococcal strain only. The right column contains the staphylococcal strain only, and the bottom row contains the streptococcal strain only. The bottom right corner well contains uninoculated BHI. A and B—*S. aureus* (Newman) after 0 and 6 h, respectively, grown on selective medium (tryptic soy agar supplemented with 5  $\mu$ g/ml optochin); C and D—*S. aureus* (Newman) after 0 and 6 h in coculture supplemented with catalase (anaerobic conditions yielded identical results to those shown in panels C to D); E and F—*S. pneumoniae* (Pn-20) after 0 and 6 h, respectively, grown on selective medium (tryptic soy agar supplemented with 5% sheep blood and 8  $\mu$ g/ml gentamicin).

TABLE 2. Various bactericidal efficiencies of different streptococcus strains against *S. aureus* strain Newman<sup>a</sup>

Streptococcus strain	Bactericidal efficiency (IK6) (log <sub>10</sub> CFU $\pm$ SD)	Concn of H <sub>2</sub> O <sub>2</sub> (mM) in supernatant of 7.5 log <sub>10</sub> CFU of <i>S. pneumoniae</i> culture
<i>S. pneumoniae</i> (Pn-20)	6.4 $\pm$ 0.3	1.60 $\pm$ 0.58
<i>S. pneumoniae</i> (Pn-20 $\Delta$ spxB)	1.2 $\pm$ 0.8	<0.05
<i>S. pneumoniae</i> (Pn-20 $\Delta$ lytA)	6.2 $\pm$ 0.1	1.60 $\pm$ 0.87
<i>S. pneumoniae</i> (TIGR4)	6.3 $\pm$ 0.3	0.12 $\pm$ 0.07
<i>S. pneumoniae</i> (TIGR4 $\Delta$ spxB)	1.4 $\pm$ 0.2	<0.05
<i>S. pneumoniae</i> (Rx1)	5.8 $\pm$ 0.5	0.20 $\pm$ 0.17
<i>S. pneumoniae</i> (Rx1 $\Delta$ lytA)	5.8 $\pm$ 0.6	0.43 $\pm$ 0.05
<i>S. gordonii</i>	3.8 $\pm$ 0.6	<0.05 <sup>†</sup>
Group A streptococcus	0*	<0.05 <sup>†</sup>
Group C streptococcus	0*	<0.05 <sup>†</sup>

<sup>a</sup> IK6, maximal *S. aureus* Newman inoculum killed by 10<sup>6</sup> CFU of streptococci at 6 h. IK values are averages from at least three independent experiments  $\pm$  SD. \*, detection level = 50 CFU/well; †, detection level = 0.05 mM.

TABLE 3. Susceptibilities of various staphylococci to *S. pneumoniae* strain Pn-20 bactericidal effect and to external H<sub>2</sub>O<sub>2</sub> and their catalase activities

Staphylococcus strain	Susceptibility to <i>S. pneumoniae</i> killing IK6 (log <sub>10</sub> CFU ± SD) <sup>a</sup>	H <sub>2</sub> O <sub>2</sub> susceptibility (Δlog <sub>10</sub> CFU) <sup>b</sup>	Catalase activity (mU per 10 <sup>8</sup> CFU)
<i>S. aureus</i> (Newman)	6.4 ± 0.3	-2.5	161
<i>S. aureus</i> (Newman) in medium supplemented with catalase	0*	+1.5	ND
<i>S. aureus</i> (Newman) under anaerobic conditions	0*	ND <sup>c</sup>	ND
<i>S. aureus</i> (ALR)	5.35 ± 0.93	-1.5	ND
<i>S. epidermidis</i>	<2	+0.3	524
<i>S. xyloso</i>	<2	+0.2	1,050
<i>S. sciurii</i>	<2	+0.4	7,334

<sup>a</sup> IK6 = maximal staphylococcal inoculum killed by 10<sup>6</sup> CFU of *S. pneumoniae* (Pn-20) at 6 h. \*, detection level = 50 CFU/well. IK values are averages from at least three independent experiments ± SD.

<sup>b</sup> Net reduction in log<sub>10</sub> CFU at 6 h compared to the initial 7.7 log<sub>10</sub> CFU of *S. aureus* in medium supplemented with H<sub>2</sub>O<sub>2</sub> periodically.

<sup>c</sup> ND, not done.




FIG. 2. *S. aureus* growth (A) in coculture with *S. pneumoniae* under aerobic conditions (▲), coculture in anaerobic conditions (◆), coculture with periodic addition of catalase (△), or plain BHI (●). (B) In sterile supernatant from *S. pneumoniae* cultures (■), in supernatant with catalase supplementation (□), in plain BHI (●), or in BHI supplemented with catalase (○).



parent strains (Table 2). This finding excludes a potential accessory role for this toxic enzyme, while also serving as a control to demonstrate that the significantly reduced bactericidal activity of  $\Delta$ spxB strains was a direct result of deficient SpxB activity and not by the genetic manipulation itself.

*S. aureus* Newman was more susceptible to *S. pneumoniae*'s bactericidal effect than strain ALR. CNS strains showed undetectable inhibition by *S. pneumoniae* (Pn-20) in cocultures (IK6 < 2). These results correlated (Table 3) with the susceptibilities of the staphylococcal strains to H<sub>2</sub>O<sub>2</sub> added to the medium (1 μmol every 90 min) as well as to the catalase activities of these strains measured with the Amplex Red catalase assay kit (Molecular Probes, Eugene, OR). External H<sub>2</sub>O<sub>2</sub> added periodically reduced CFU/ml of *S. aureus* strains by 1.5 to 2.5 log<sub>10</sub>, while the neutralization of this external H<sub>2</sub>O<sub>2</sub> by exogenous catalase permitted an increase of 1.5 log<sub>10</sub> CFU/ml. In contrast, under the same conditions (with no addition of catalase), the numbers of CFU/ml for CNS strains increased slightly (0.5 log<sub>10</sub>) (Table 3).

It is striking that *S. aureus*, a catalase-positive species, is so susceptible to a H<sub>2</sub>O<sub>2</sub>-producing bacteria. The two different *S. aureus* strains tested were highly susceptible to *S. pneumoniae*, while CNS species were highly resistant to *S. pneumoniae*. All staphylococci elaborate catalase, with variation between species in the number and expression of catalase enzymes (1, 3). Indeed the staphylococcal species that were resistant to *S. pneumoniae* secreted higher concentrations of catalase than *S. aureus*; however, the concentrations detected may not linearly reflect differences in intracellular catalase, and the greater antioxidant capacity of these species might be due to additional factors not measured in this study.

Our impetus for this study was the epidemiologic data showing an inverse association between *S. aureus* and *S. pneumoniae* colonization (4, 17). H<sub>2</sub>O<sub>2</sub>-mediated, unidirectional antagonism as observed here in vitro provides one possible mechanism for this inverse association. If the association is causal and acquisition of *S. pneumoniae* eradicates *S. aureus* carriage, then use of pneumococcal vaccines may eliminate the "protective" effect of *S. pneumoniae* against *S. aureus* carriage and an increase in *S. aureus* carriage will follow. Increased *S. aureus* otitis media has been observed among vaccinees in a pneumococcal conjugate vaccine randomized trial (23). Whether the current increase in severe community-acquired *S. aureus* infections, including methicillin-resistant *S. aureus* (6), is partially caused by the recent introduction of the pneumococcal conjugate vaccine is yet to be determined.

This study provides only the first step towards elucidating the mechanism of *S. pneumoniae*-*S. aureus* interference in vivo. In vivo interference could be caused by a direct bactericidal effect similar to that observed here. Alternatively, or in addition, it could occur via a host cell signaling pathway. Interestingly, such an indirect pathway might also involve H<sub>2</sub>O<sub>2</sub>, which plays key roles in cell signaling, particularly in regulation of the production of cytokines (7, 25). Future in vivo studies are required to address these important remaining questions.

We thank Michael Wessels for providing *Streptococcus* group A, Jean Lee for providing the staphylococcus strains used in the study and for critical review of the manuscript, and Amit Srivastava for thoughtful advice.

This study was supported by NIH grant 1R01AI48935 to M.L. and 1R01AI067737-01 and the Pamela and Jack Egan Fund to R.M.

#### REFERENCES

1. Barriere, C., R. Bruckner, D. Centeno, and R. Talon. 2002. Characterisation of the katA gene encoding a catalase and evidence for at least a second catalase activity in *Staphylococcus xylosum*, bacteria used in food fermentation. *FEMS Microbiol. Lett.* **216**:277–283.
2. Bermpohl, D., A. Halle, D. Freyer, E. Dagand, J. S. Braun, I. Bechmann, N. W. Schroder, and J. R. Weber. 2005. Bacterial programmed cell death of cerebral endothelial cells involves dual death pathways. *J. Clin. Investig.* **115**:1607–1615.
3. Bisailon, J. G., G. Dubois, R. Beaudet, M. Sylvestre, R. Charbonneau, and M. Gagnon. 1985. Quantitative determination of catalase activity produced by *Neisseria gonorrhoeae*, *Staphylococcus epidermidis*, *Neisseria meningitidis* and other bacterial strains using the Catalasemeter. *Exp. Biol.* **43**:225–230.
4. Bogaert, D., A. van Belkum, M. Sluiter, A. Luijckx, R. de Groot, H. C. Rumke, H. A. Verbrugh, and P. W. Hermans. 2004. Colonisation by *Streptococcus pneumoniae* and *Staphylococcus aureus* in healthy children. *Lancet* **363**:1871–1872.
5. Braun, J. S., J. E. Sublett, D. Freyer, T. J. Mitchell, J. L. Cleveland, E. I. Tuomanen, and J. R. Weber. 2002. Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis. *J. Clin. Investig.* **109**:19–27.
6. Buescher, E. S. 2005. Community-acquired methicillin-resistant *Staphylococcus aureus* in pediatrics. *Curr. Opin. Pediatr.* **17**:67–70.
7. DeYulia, G. J., Jr., J. M. Carcamo, O. Borquez-Ojeda, C. C. Shelton, and D. W. Golde. 2005. Hydrogen peroxide generated extracellularly by receptor-ligand interaction facilitates cell signaling. *Proc. Natl. Acad. Sci. USA* **102**:5044–5049.
8. Duane, P. G., J. B. Rubins, H. R. Weisel, and E. N. Janoff. 1993. Identification of hydrogen peroxide as a *Streptococcus pneumoniae* toxin for rat alveolar epithelial cells. *Infect. Immun.* **61**:4392–4397.
9. Feldman, C., R. Anderson, R. Cockeran, T. Mitchell, P. Cole, and R. Wilson. 2002. The effects of pneumolysin and hydrogen peroxide, alone and in combination, on human ciliated epithelium in vitro. *Respir. Med.* **96**:580–585.
10. Hoskins, J., W. E. Alborn, Jr., J. Arnold, L. C. Blaszcak, S. Burgett, B. S. DeHoff, S. T. Estrem, L. Fritz, D. J. Fu, W. Fuller, C. Geringer, R. Gilmour, J. S. Glass, H. Khoja, A. R. Kraft, R. E. Lagace, D. J. LeBlanc, L. N. Lee, E. J. Lefkowitz, J. Lu, P. Matsushima, S. M. McAhren, M. McHenry, K. McLeaster, C. W. Mundy, T. I. Nicas, F. H. Norris, M. O'Gara, R. B. Peery, G. T. Robertson, P. Rooker, P. M. Sun, M. E. Winkler, Y. Yang, M. Young-Bellido, G. Zhao, C. A. Zook, R. H. Baltz, S. R. Jaskunas, P. R. Rosteck, Jr., P. L. Skatrud, and J. I. Glass. 2001. Genome of the bacterium *Streptococcus pneumoniae* strain R6. *J. Bacteriol.* **183**:5709–5717.
11. McLeod, J. W., and J. Gordon. 1922. Production of hydrogen peroxide by bacteria. *Biochem. J.* **16**:499–506.
12. Obaro, S., and R. Adegbola. 2002. The pneumococcus: carriage, disease and conjugate vaccines. *J. Med. Microbiol.* **51**:98–104.
13. Oggioni, M. R., and G. Pozzi. 1996. A host-vector system for heterologous gene expression in *Streptococcus gordonii*. *Gene* **169**:85–90.
14. Pericone, C. D., D. Bae, M. Shchepetov, T. McCool, and J. N. Weiser. 2002. Short-sequence tandem and non-tandem DNA repeats and endogenous hydrogen peroxide production contribute to genetic instability of *Streptococcus pneumoniae*. *J. Bacteriol.* **184**:4392–4399.
15. Pericone, C. D., K. Overweg, P. W. Hermans, and J. N. Weiser. 2000. Inhibitory and bactericidal effects of hydrogen peroxide production by *Streptococcus pneumoniae* on other inhabitants of the upper respiratory tract. *Infect. Immun.* **68**:3990–3997.
16. Ravin, A. W. 1959. Reciprocal capsular transformations of pneumococci. *J. Bacteriol.* **77**:296–309.
17. Regev-Yochay, G., R. Dagan, M. Raz, Y. Carmeli, B. Shainberg, E. Derazne, G. Rahav, and E. Rubinstein. 2004. Association between carriage of *Streptococcus pneumoniae* and *Staphylococcus aureus* in children. *JAMA* **292**:716–720.
18. Shoemaker, N. B., and W. R. Guild. 1974. Destruction of low efficiency markers is a slow process occurring at a heteroduplex stage of transformation. *Mol. Gen. Genet.* **128**:283–290.
19. Spellerberg, B., D. R. Cundell, J. Sandros, B. J. Pearce, I. Idanpaan-Heikkila, C. Rosenow, and H. R. Masure. 1996. Pyruvate oxidase, as a determinant of virulence in *Streptococcus pneumoniae*. *Mol. Microbiol.* **19**:803–813.
20. Sung, C. K., H. Li, J. P. Claverys, and D. A. Morrison. 2001. An *rpsL* cassette, Janus, for gene replacement through negative selection in *Streptococcus pneumoniae*. *Appl. Environ. Microbiol.* **67**:5190–5196.
21. Tettelin, H., K. E. Nelson, I. T. Paulsen, J. A. Eisen, T. D. Read, S. Peterson, J. Heidelberg, R. T. DeBoy, D. H. Haft, R. J. Dodson, A. S. Durkin, M. Gwinn, J. F. Kolonay, W. C. Nelson, J. D. Peterson, L. A. Umayam, O. White, S. L. Salzberg, M. R. Lewis, D. Radune, E. Holtzapple, H. Khouri, A. M. Wolf, T. R. Utterback, C. L. Hansen, L. A. McDonald, T. V. Feldblyum, S.

- Angiuoli, T. Dickinson, E. K. Hickey, I. E. Holt, B. J. Loftus, F. Yang, H. O. Smith, J. C. Venter, B. A. Dougherty, D. A. Morrison, S. K. Hollingshead, and C. M. Fraser. 2001. Complete genome sequence of a virulent isolate of *Streptococcus pneumoniae*. *Science* **293**:498–506.
22. Trzcinski, K., C. M. Thompson, and M. Lipsitch. 2003. Construction of otherwise isogenic serotype 6B, 7F, 14, and 19F capsular variants of *Streptococcus pneumoniae* strain TIGR4. *Appl. Environ. Microbiol.* **69**:7364–7370.
23. Veenhoven, R., D. Bogaert, C. Uiterwaal, C. Brouwer, H. Kiezebrink, J. Bruin, E. IJzerman, P. Hermans, R. de Groot, B. Zegers, W. Kuis, G. Rijkers, A. Schilder, and E. Sanders. 2003. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. *Lancet* **361**:2189–2195.
24. Wertheim, H. F., D. C. Melles, M. C. Vos, W. van Leeuwen, A. van Belkum, H. A. Verbrugh, and J. L. Nouwen. 2005. The role of nasal carriage in *Staphylococcus aureus* infections. *Lancet Infect. Dis.* **5**:751–762.
25. Xue, X., J. H. Piao, A. Nakajima, S. Sakon-Komazawa, Y. Kojima, K. Mori, H. Yagita, K. Okumura, H. Harding, and H. Nakano. 2005. Tumor necrosis factor alpha (TNFalpha) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNFalpha. *J. Biol. Chem.* **280**:33917–33925.